"10.1371_journal.pone.0143073","plos one","2015-12-02T00:00:00Z","Jos√© √Ångel Hern√°ndez; Mar√≠a Hern√°ndez-S√°nchez; Ana Eugenia Rodr√≠guez-Vicente; Vera Grossmann; Rosa Collado; Cecilia Heras; Anna Puiggros; Ana √Åfrica Mart√≠n; Noem√≠ Puig; Roc√≠o Benito; Cristina Robledo; Julio Delgado; Teresa Gonz√°lez; Jos√© Antonio Queiz√°n; Josefina Galende; Ignacio de la Fuente; Guillermo Mart√≠n-N√∫√±ez; Jos√© Mar√≠a Alonso; Pau Abrisqueta; Elisa Lu√±o; Isabel Marug√°n; Isabel Gonz√°lez-Gasc√≥n; Francesc Bosch; Alexander Kohlmann; Marcos Gonz√°lez; Blanca Espinet; Jes√∫s Mar√≠a Hern√°ndez-Rivas; Grupo Cooperativo Espa√±ol de Citogen√©tica Hematol√≥gica (GCECGH) and Grupo Espa√±ol de Leucemia Linf√°tica Cr√≥nica (GELLC)","Hematology Department, Hospital Universitario Infanta Leonor, Universidad Complutense de Madrid, Madrid, Spain; IBSAL, IBMCC, Centro de Investigaci√≥n del C√°ncer, Universidad de Salamanca,CSIC, Hospital Universitario de Salamanca, Spain; MLL Munich, Germany; Hematology Department, Hospital General, Valencia, Spain; Pathology Department, Hospital del Mar, Barcelona, Spain; Hematology Department, Hospital Universitario, Salamanca, Spain; Hematology Department, Hospital Clinic i Provincial, Barcelona, Spain; Fundaci√≥n P√∫blica Galega de Medicina Xen√≥mica, Santiago de Compostela, Spain; Hematology Department, Hospital General, Segovia, Spain; Hematology Department, Hospital del Bierzo, Ponferrada, Le√≥n, Spain; Hematology Department, Hospital Universitario R√≠o Hortega, Valladolid, Spain; Hematology Department, Hospital Virgen del Puerto, Plasencia, C√°ceres, Spain; Hematology Department, Hospital R√≠o Carri√≥n, Palencia, Spain; Hematology Department, Hospital Vall dHebron, Barcelona, Spain; Hematology Department, Hospital Central de Asturias, Oviedo, Spain; Hematology Department, Hospital Cl√≠nico, Valencia, Spain; AstraZeneca, Personalized Healthcare and Biomarkers, Innovative Medicines, Macclesfield, United Kingdom; Department of Medicine, Universidad de Salamanca, Spain","Conceived and designed the experiments: JAH MHS AERV JMHR. Performed the experiments: MHS AERV CR RB. Analyzed the data: JAH MHS AERV CR RB. Contributed reagents/materials/analysis tools: VG AK RC CH AP AAM NP JD TG JAQ JG IF GMN JMA PA EL IM IG MG. Wrote the paper: JAH MHS AERV CR RB VG FB BE MG JMHR.","The authors have declared that no competing interests exist. Oligonucleotide primer plates for amplicon deep-sequencing were provided by Roche Diagnostics, Penzberg, Germany, as part of the IRON-II study. VG and AK were employed by MLL Munich Leukemia Laboratory and AK is employed by AstraZeneca. This does not alter the authors adherence to PLOS ONE policies on sharing data and materials.","2015","12","Jos√© √Ångel Hern√°ndez","J√√H√",28,FALSE,4,4,5,10,FALSE,FALSE,TRUE,2,"1;8",TRUE
